Cart
sales@molnova.com
Ulocuplumab
CAS No. 1375830-34-4
Ulocuplumab( —— )
Catalog No. M36724 CAS No. 1375830-34-4
Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 613 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1387 | In Stock |
|
| 50MG | 1832 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameUlocuplumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionUlocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.
-
DescriptionUlocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models.
-
In VitroApoptosis Analysis Cell Line:Ramos cells and primary leukemia cells (from CLL patients)Concentration:0-100 μM Incubation Time:48 hours Result:Induced apoptosis in Ramos cells with an IC50 value of 1.9 nM and showed pro-apoptotic with an IC50 value of 12.43 nM in primary leukemia cells from CLL patients.
-
In VivoAnimal Model:Severe combined immunodeficient (SCID) mice of AML model (MOLP-8 cells) Dosage:3-30 mg/kg Administration:Intraperitoneal injection; every 3-4 days for 5 doses; last for 65 days Result:Significantly delayed mean tumor growth by 66% and 56% when compared with isotype control on day 25.
-
Synonyms——
-
PathwayAutophagy
-
TargetCXCR
-
RecptorCXCR | Apoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1375830-34-4
-
Formula Weight146.2 (kDa)
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kashyap MK, et al. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19;7(3):2809-22. ?
molnova catalog
related products
-
TC14012
TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. TC14012 is a potent CXCR7 agonist with an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has anti-HIV activity and anti-cancer activity.
-
VUF-11222
VUF-11222 is a CXCR3 nonmimetic peptide agonist that induces gliosis.VUF 11222 has been used in the study of retinal inflammation.
-
USL311
USL311 is a CXCR4 receptor antagonist which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4.?USL311 inhibits CXCR4 activation and decreases proliferation and migration of CXCR4-expressing tumor cells, with anti-tumor activity.
